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Abstract
While the risk of ovarian cancer clearly reduces with each full-term pregnancy, the effect of incomplete pregnancies is
unclear. We investigated whether incomplete pregnancies (miscarriages and induced abortions) are associated with risk of
epithelial ovarian cancer. This observational study was carried out in female participants of the European Prospective
Investigation into Cancer and Nutrition (EPIC). A total of 274,442 women were followed from 1992 until 2010. The baseline
questionnaire elicited information on miscarriages and induced abortions, reproductive history, and lifestyle-related factors.
During a median follow-up of 11.5 years, 1,035 women were diagnosed with incident epithelial ovarian cancer. Despite the
lack of an overall association (ever vs. never), risk of ovarian cancer was higher among women with multiple incomplete
pregnancies (HR$4vs.0: 1.74, 95% CI: 1.20–2.70; number of cases in this category: n = 23). This association was particularly
evident for multiple miscarriages (HR$4vs.0: 1.99, 95% CI: 1.06–3.73; number of cases in this category: n = 10), with no
significant association for multiple induced abortions (HR$4vs.0: 1.46, 95% CI: 0.68–3.14; number of cases in this category:
n = 7). Our findings suggest that multiple miscarriages are associated with an increased risk of epithelial ovarian cancer,
possibly through a shared cluster of etiological factors or a common underlying pathology. These findings should be
interpreted with caution as this is the first study to show this association and given the small number of cases in the highest
exposure categories.
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Introduction
Increasing parity reduces the risk of ovarian cancer [1–3], but
the association of incomplete pregnancies with risk remains to be
characterized. Within EPIC, an 8% lower ovarian cancer risk per
full-term pregnancy has been observed [4]. One could hypothesize
that pregnancies that terminate early in gestation reduce ovarian
cancer risk to a lesser extent. However, epidemiologic findings
remain inconsistent, with some reports showing no associations
and others showing either inverse or positive associations (as
reviewed in [5]).
Incomplete pregnancies include miscarriages (spontaneous
losses) and induced abortions (induced losses because of medical
indications or unwanted pregnancy), which have diverse aetiolo-
gies and, therefore, their association with ovarian cancer risk
might differ. Of particular interest are women who have multiple
incomplete pregnancies, as the effect of a single event may be too
small to detect and/or the risk may not change in a linear manner
with each additional incomplete pregnancy.
The aim of the current analysis was to explore the association of
multiple miscarriages and induced abortions with risk of epithelial
ovarian cancer in the European Prospective Investigation into
Cancer and Nutrition (EPIC).
Materials and Methods
Ethics Statement
All participants signed an informed written consent. The
present study was approved by the Institutional Review Board of
the International Agency for Research on Cancer (IARC) and
local institutional review boards in participating centres.
Study Population
EPIC is a prospective cohort study initiated in 1992 in 10
European countries: Denmark, France, Germany, Greece, Italy,
the Netherlands, Norway, Spain, Sweden, and the United
Kingdom. Between 1992 and 2000, a total of 519,978 men and
women were recruited. Of these, most were aged 25–70 years and
recruited from the general population. Exceptions were the
Oxford cohort, UK (based on vegetarian volunteers and healthy
eaters), the Utrecht cohort, The Netherlands (based on women
attending breast cancer screening), the French cohort (based on
female members of the health insurance for state school
employees), and components of the Italian and Spanish cohorts
(members of local blood donor associations). A full description of
the study design and cohort has been published elsewhere [6,7].
Our analysis is based on data from all 274,442 female
participants after a priori exclusion of women with prevalent
malignancy (n = 19,707) or bilateral oophorectomy (n= 10,500) at
baseline, incomplete follow-up (n = 2,209), missing lifestyle data
(n = 526), and women from centres with missing information on
miscarriages and induced abortions (i.e., Bilthoven, Umea, and
Norway). For the analysis on induced abortions, we additionally
excluded women from Malmo as information on induced
abortions was not available for this centre.
Data Collection
Eligible subjects who decided to participate signed an informed
consent form and completed diet and lifestyle questionnaires,
which were either interviewer-administered (Naples, Ragusa,
Spain and Greece) or mailed self-administered (all other centres).
In most countries, participants were invited to a centre for blood
collection and anthropometric measurements. Through the
baseline questionnaire, women were asked whether they had ever
had a miscarriage or an induced abortion, and if so, how many
miscarriages and/or induced abortions they have had, as well as
the age at first and last abortion. The structure and availability of
the questions varied by center. For that reason, all variables were
standardized centrally. If a participant recorded either a number
of miscarriages/induced abortions or their age at a miscarriage,
then, it was assumed that they had experienced a miscarriage.
Number of miscarriages/induced abortions have been trans-
formed into 1, 2, 3, 4, and 5 or more. Questions on miscarriages
and induced abortions were missing for Bilthoven, Umea, and
Norway, while, questions on abortions only were missing for
Malmo. Therefore, these centres have been excluded from the
specific analyses on miscarriages and/or abortions.’’
Determination of Menopausal Status
Women were considered as premenopausal at baseline when
they reported having had regular menses over the past 12 months
or if they were less than 46 years of age. Women were considered
postmenopausal when they reported not having had any menses
over the past 12 months, or when they were older than 55 years.
Women who were between 46 and 55 years of age and who had
missing or incomplete questionnaire data for menopausal status
were classified as perimenopausal/unknown.
Follow-up
Participants were followed up from study entry and until
diagnosis of any cancer (except non-melanoma skin cancer), death,
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emigration, or until the end of the follow-up period, whichever
occurred first. Incident epithelial ovarian cancer was defined as
ovarian, fallopian tube and primary peritoneal cancer (ICD-O-2
codes C56.9, C57.0, and C48, respectively). Incident cancer cases
were identified through either population-based cancer registries
or a combination of methods including health insurance records,
cancer and pathology registries, and active follow-up through
study participants and their next-of-kin. Mortality data were also
obtained from either the cancer registry or mortality registries at
the regional or national level. The end of the follow-up period was
different for different centres and ranged between December 2004
and June 2010.
Data Analysis
Person-years at risk were calculated from the start of the study
until censoring at the date of diagnosis of any ovarian cancer,
death, emigration, other loss to follow-up or the date at which
follow-up ended, defined as the last date at which follow-up data
were judged to be complete or the last date of contact in the
centers that used active follow-up.
Hazard ratios (HR) and 95% confidence intervals (CI) were
estimated using Cox proportional hazards models with age as the
underlying time variable and stratified by centre and age.
Multivariate models were adjusted for parity (number of full-term
pregnancies), duration of oral contraceptive use (continuous), body
mass index (continuous), menopausal status (pre-, peri-, or
postmenopausal), education (none, primary school, technical/
professional school, secondary school, university), and age at
menarche (continuous). Missing covariate values were imputed
using mean substitution [8].
We performed a sensitivity analysis restricted to postmenopausal
women as these women had complete information on number of
miscarriages and induced abortions since they were at the end of
their fertile life. In this sensitivity analysis we additionally adjusted
for age at menopause (continuous) and duration of hormone
therapy (continuous).
An additional sensitivity analysis was performed by excluding
the first 5 years of follow-up.
All statistical analyses were carried out using SAS 9.2 (SAS
Institute Inc, Cary, NC).
Table 2. Incomplete Pregnancies and the Risk of Ovarian Cancer in the European Prospective Investigation into Cancer (EPIC),
1992–2010.
Model 1a Model 2b
n cases PY HR (95% CI) HR (95% CI)
Incomplete pregnancies c
Never 492 1,456,074 Reference Reference
Ever 298 936,943 1.00 (0.86–1.16) 1.02 (0.88–1.19)
Number of incomplete pregnancies d
0 (reference) 488 1,446,005 Reference Reference
1 172 622,724 0.91 (0.76–1.08) 0.92 (0.77–1.11)
2–3 101 301,724 1.11 (0.89–1.38) 1.15 (0.92–1.43)
$4 23 46,927 1.74 (1.13–2.67) 1.74 (1.20–2.70)
Miscarriages
Never 665 1,949,976 Reference Reference
Ever 206 622,878 0.96 (0.82–1.13) 0.97 (0.83–1.14)
Number of miscarriages d
0 (reference) 665 1,949,976 Reference Reference
1 136 460,243 0.86 (0.72–1.04) 0.86 (0.71–1.05)
2–3 58 140,525 1.20 (0.91–1.57) 1.23 (0.93–1.61)
$4 10 15,132 1.94 (1.03–3.63) 1.99 (1.06–3.73)
Induced abortions
Never 646 1,910,876 Reference Reference
Ever 140 466,700 1.01 (0.83–1.22) 1.04 (0.86–1.27)
Number of induced abortions d
0 (reference) 646 1,910,876 Reference Reference
1 85 321,772 0.88 (0.70–1.11) 0.92 (0.73–1.16)
2–3 47 123,316 1.32 (0.97–1.80) 1.32 (0.97–1.81)
$4 7 18,269 1.40 (0.65–3.01) 1.46 (0.68–3.14)
aStratified for centre and age.
bAdjusted for parity (number of full term pregnancies) and oral contraceptive use (duration of use), body mass index (continuous), menopausal status (pre-, peri- or
postmenopausal), educational level (none, primary school, technical/professional school, secondary school, university), and age at menarche (years, continuous).
cDefined as either having had a miscarriage or an induced abortion.
dNumber of incomplete pregnancies is missing for 2 cases. Number of miscarriages is missing for 2 cases. Number of induced abortions is missing for 1 case.
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio, PY, person-years.
doi:10.1371/journal.pone.0037141.t002
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Results
During a median follow-up of 11.5 years, 1,035 women were
diagnosed with incident epithelial ovarian cancer (92.9% ovarian,
3.6% fallopian tube, and 3.5% peritoneal cancers).
Compared with women who never had a miscarriage, women
with multiple miscarriages ($2) were slightly older, had higher
body mass index, were more likely to be postmenopausal, less
likely to have had a full-term pregnancy, less likely to have used
oral contraceptives, and more likely to have used hormonal
therapy (Table 1). These differences were larger for women with
four or more miscarriages. Compared with women who had never
had an induced abortion, women who had had 4 or more induced
abortions were slightly older, had a lower body mass index, were
more likely to be postmenopausal, less likely to have used oral
contraceptives, and more likely to have used hormonal therapy
(Table 1).
We observed no association between ever having had an
incomplete pregnancy or having had one incomplete pregnancy
and risk of ovarian cancer, as compared with never having had an
incomplete pregnancy (Table 2). However, women with 4 or more
incomplete pregnancies had a significantly higher risk (HR$4vs.0:
1.74, 95% CI: 1.20–2.70; number of cases in this category: n = 23).
When the number of incomplete pregnancies was divided into
miscarriages and induced abortions, women with a history of $4
miscarriages had a statistically significant 2-fold increased risk
(HR: 1.99, 95% CI: 1.06–3.73; number of cases in this category:
n = 10), although this estimate is based on a small number of cases.
No association was observed for women who had only one
miscarriage. Results were stronger among women who were
postmenopausal at baseline (HR$4vs.0: 2.35, 95% CI: 1.16–4.77;
number of cases in this category: n = 8). No substantial differences
were observed when restricting analyses to ever-pregnant women
and when stratifying by age at first pregnancy (,30 vs. $30 years;
results not shown). To prevent reverse causation we performed an
additional sensitivity analysis (all menopausal states included), for
which we excluded the first 5 years of follow-up (9,343 women
excluded). This resulted in a stronger association (HR$4vs.0 2.25,
95% CI: 1.06–4.79; number of cases in this category: n= 7).
Multiple induced abortions were not significantly associated
with epithelial ovarian cancer risk (Table 2; HR$4vs.0: 1.46, 95%
CI: 0.68–3.14; number of cases in this category: n = 7).
Discussion
In this large prospective cohort study, we observed a 2-fold
increased risk of epithelial ovarian cancer among women with 4 of
more miscarriages.
This is the first prospective study that investigated the
association of multiple miscarriages with ovarian cancer. Most
case-control studies only investigated ever versus never had a
miscarriage and did not observe an association [5]. Only one study
investigated $3 miscarriages and none of the studies investigated
$4 miscarriages [5]. Moreover, these studies were generally
underpowered. The results of our study suggest that an association
may be present only for women with multiple miscarriages, who
are likely to have a more pronounced cluster of etiological factors
leading to recurrent events. As the etiology of recurrent
miscarriage itself is not fully understood, it is difficult to argue
about plausible mechanisms underlying the observed association
in this study. Women who experience multiple miscarriages may
have an underlying pathology which predisposes them to ovarian
cancer as well. A possible mechanism underlying this association
might be an endocrinopathy, such as luteal phase deficiency,
which is characterized by inadequate corpus luteum progesterone
production resulting in progesterone deficiency [9–11]. Progester-
one is thought to play a major protective role in ovarian cancer
aetiology [12,13]. Factors related to a lack of progesterone have
been consistently shown to increase ovarian cancer risk [12–13].
However, the incidence of luteal phase deficiency in recurrent
miscarriage is estimated to be only 10–28% [10], thus this would
only explain part of the association. It is important to note that all
possible mechanisms discussed here are speculative and further
research is needed to fully understand this association.
In line with most studies we observed no overall association
between induced abortions and ovarian cancer risk, whereas two
studies reported a reduced risk [5]. However, our result should be
interpreted with care for several reasons. It has been shown that
induced abortions are often under- or misreported [14–16], and it
could be that women who underwent surgical curettage for
miscarriage or other medical indications misreported this miscar-
riage as an induced abortion. On the other hand, in many
countries induced abortion is illegal and this may also lead to
under-reporting.
Our results suggest that miscarriages and induced abortions
may have different effects on ovarian cancer risk and therefore
examining the association between incomplete pregnancies and
risk of ovarian cancer may obscure any real association.
A major strength of this large cohort study is the prospective
design, with detailed exposure and covariate assessment prior to
diagnosis. A limitation of our study is the relatively small number
of cases in the top categories of incomplete pregnancies. In
addition, we do not know in which week of the pregnancy the
miscarriage or induced abortion occurred. Miscarriages most
frequently occur during the 6th to 12th week of pregnancy and our
results, therefore, are most likely driven by these early pregnancies.
We have not been able to review medical charts to confirm a
women’s self-report of miscarriage/induced abortion. However,
underreporting seems more likely than over-reporting. If we
indeed have missed some miscarriages or induced abortions, this
would cause non-differential misclassification since data on
pregnancy loss were collected prior to cancer diagnosis. The
result would be an attenuation of the risk estimates. An additional
limitation of our study is that information about pregnancy loss
was collected at baseline only. Among premenopausal women this
information might therefore be incomplete, which again may lead
to an attenuation of the association. Among postmenopausal
women, for whom these data were complete, indeed, we observed
a stronger association between multiple miscarriages and ovarian
cancer risk.
In conclusion, our findings suggest that multiple miscarriages
are associated with an increased risk of epithelial ovarian cancer.
As this is the first prospective study that observed this association,
more studies are needed to confirm or dispute our findings.
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